AIRX 75 SOLUTION Kanada - Inggris - Health Canada

airx 75 solution

flexo products ltd. - benzalkonium chloride; alkyl dimethyl ethylbenzyl ammonium chloride - solution - 0.105%; 0.105% - benzalkonium chloride 0.105%; alkyl dimethyl ethylbenzyl ammonium chloride 0.105% - disinfectants (for agents used on object)

AIRX SPRAY N GO SOLUTION Kanada - Inggris - Health Canada

airx spray n go solution

flexo products ltd. - benzalkonium chloride; alkyl dimethyl ethylbenzyl ammonium chloride - solution - 0.15%; 0.15% - benzalkonium chloride 0.15%; alkyl dimethyl ethylbenzyl ammonium chloride 0.15% - disinfectants (for agents used on object)

Flexove 625 mg tablets Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

flexove 625 mg tablets

laboratoires expanscience - glucosamine - tablet - 625 milligram(s) - other antiinflammatory and antirheumatic agents, non-steroids; glucosamine

COMAGIS CREAM Israel - Inggris - Ministry of Health

comagis cream

padagis israel pharmaceuticals ltd, israel - bifonazole; fluocinonide - cream - fluocinonide 0.05 w/w; bifonazole 1.00 w/w - bifonazole - bifonazole - broad-spectrum drug for relief of inflammatory conditions accompanied by fungal infection, which respond to corticoid therapy.

BOTOX 100 Israel - Inggris - Ministry of Health

botox 100

abbvie biopharmaceuticals ltd, israel - botulinum toxin type a - powder for solution for injection - botulinum toxin type a 100 u/vial - botulinum toxin - botulinum toxin - neurologic disorders:• •focal spasticity associated with dynamic equinus foot deformity due to spasticity in ambulant paediatric cerebral palsy patients two years of age or older. • • focal spasticity of the wrist and hand in adult • focal spasticity of the lower limb, including ankle and foot in adult. • •blepharospasm or vii nerve disorders in patients over 12 years, hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. • •reduction of the signs and symptoms of cervical dystonia (spasmodic torticollis) in adults. • •symptom relief in adults fulfilling criteria for chronic migraine (headaches on ≥15 days per month of which at least 8 days with migraine) in patients who have responded inadequately or are intolerant of prophylactic migraine medications. bladder disorders: •management of overactive bladder with symptoms of urinary incontinence, urgency and frequency in adult patients who have an inadequate response to, or are intolerant of, anticholinergic medication. •urinary incontinence in adults with neurogenic detrusor overactivity resulting from neurogenic bladder due to stable sub-cervical spinal cord injury, or multiple sclerosis. skin and skin appendage disorder: •management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment. •for the temporary improvement in the appearance of: - moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines) and/or, - moderate to severe lateral canthal lines (crow’s feet lines) seen at maximum smile and/or, - moderate to severe forehead lines seen at maximum eyebrow elevation when the severity of the facial lines has an important psychological impact in adult patients.

BOTOX 50 Israel - Inggris - Ministry of Health

botox 50

abbvie biopharmaceuticals ltd, israel - botulinum toxin type a - powder for solution for injection - botulinum toxin type a 50 u/vial - botulinum toxin - botulinum toxin - neurologic disorders:• •focal spasticity associated with dynamic equinus foot deformity due to spasticity in ambulant paediatric cerebral palsy patients two years of age or older. • • focal spasticity of the wrist and hand in adult • focal spasticity of the lower limb, including ankle and foot in adult. • •blepharospasm or vii nerve disorders in patients over 12 years, hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. • •reduction of the signs and symptoms of cervical dystonia (spasmodic torticollis) in adults. • •symptom relief in adults fulfilling criteria for chronic migraine (headaches on ≥15 days per month of which at least 8 days with migraine) in patients who have responded inadequately or are intolerant of prophylactic migraine medications. bladder disorders: •management of overactive bladder with symptoms of urinary incontinence, urgency and frequency in adult patients who have an inadequate response to, or are intolerant of, anticholinergic medication. •urinary incontinence in adults with neurogenic detrusor overactivity resulting from neurogenic bladder due to stable sub-cervical spinal cord injury, or multiple sclerosis. skin and skin appendage disorder: •management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment. •for the temporary improvement in the appearance of: - moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines) and/or, - moderate to severe lateral canthal lines (crow’s feet lines) seen at maximum smile and/or, - moderate to severe forehead lines seen at maximum eyebrow elevation when the severity of the facial lines has an important psychological impact in adult patients.

BOTOX 200 Israel - Inggris - Ministry of Health

botox 200

abbvie biopharmaceuticals ltd, israel - botulinum toxin type a - powder for solution for injection - botulinum toxin type a 200 u/vial - botulinum toxin - botulinum toxin - neurologic disorders:• •focal spasticity associated with dynamic equinus foot deformity due to spasticity in ambulant paediatric cerebral palsy patients two years of age or older. • • focal spasticity of the wrist and hand in adult • focal spasticity of the lower limb, including ankle and foot in adult. • •blepharospasm or vii nerve disorders in patients over 12 years, hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. • •reduction of the signs and symptoms of cervical dystonia (spasmodic torticollis) in adults. • •symptom relief in adults fulfilling criteria for chronic migraine (headaches on ≥15 days per month of which at least 8 days with migraine) in patients who have responded inadequately or are intolerant of prophylactic migraine medications. bladder disorders: •management of overactive bladder with symptoms of urinary incontinence, urgency and frequency in adult patients who have an inadequate response to, or are intolerant of, anticholinergic medication. •urinary incontinence in adults with neurogenic detrusor overactivity resulting from neurogenic bladder due to stable sub-cervical spinal cord injury, or multiple sclerosis. skin and skin appendage disorder: •management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment. •for the temporary improvement in the appearance of: - moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines) and/or, - moderate to severe lateral canthal lines (crow’s feet lines) seen at maximum smile and/or, - moderate to severe forehead lines seen at maximum eyebrow elevation when the severity of the facial lines has an important psychological impact in adult patients.

OXYCONTIN 20 Israel - Inggris - Ministry of Health

oxycontin 20

rafa laboratories ltd - oxycodone hydrochloride - tablets controlled release - oxycodone hydrochloride 20 mg - oxycodone - oxycodone - for the relief of moderate severe chronic pain.

OXYCONTIN 10 Israel - Inggris - Ministry of Health

oxycontin 10

rafa laboratories ltd - oxycodone hydrochloride - tablets controlled release - oxycodone hydrochloride 10 mg - oxycodone - oxycodone - for the relief of moderate to severe chronic pain.

OXYCONTIN 80 Israel - Inggris - Ministry of Health

oxycontin 80

rafa laboratories ltd - oxycodone hydrochloride - tablets controlled release - oxycodone hydrochloride 80 mg - oxycodone - oxycodone - for the relief of moderate to severe chronic pain.